(Juhi Aishwary, Journalist)
New Delhi: Glenmark Pharmaceuticals has started the third clinical trial of the antiviral drug favipiravir in India. It is considered potentially helpful in treating coronavirus disease. Glenmark has started the trial after it was approved in April by the country’s drug regulator.
Mumbai-based Glenmark said a filing at the BSE cleared it to become India’s first pharmaceutical company (pharmaceutical). The company has been approved by the Drug Controller General of India to begin trials on Kovid-19 patients.
The antiviral drug favipiravir is manufactured under the name Avigan, manufactured by a subsidiary of Fujifilm Holdings Corporation of Japan. It was approved for use as an anti-flu medicine in the year 2014.